What is the share price of Nectar Lifesciences Ltd (NECLIFE) today?
The share price of NECLIFE as on 9th July 2025 is ₹16.47. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nectar Lifesciences Ltd (NECLIFE) share?
The past returns of Nectar Lifesciences Ltd (NECLIFE) share are- Past 1 week: -20.26%
- Past 1 month: -24.18%
- Past 3 months: -27.35%
- Past 6 months: -56.58%
- Past 1 year: -46.91%
- Past 3 years: -30.65%
- Past 5 years: -25.14%
What are the peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE)?
The peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE) include:What is the market cap of Nectar Lifesciences Ltd (NECLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nectar Lifesciences Ltd (NECLIFE) is ₹369.36 Cr as of 9th July 2025.What is the 52 week high and low of Nectar Lifesciences Ltd (NECLIFE) share?
The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is ₹56.50 and the 52-week low is ₹15.51.What is the PE and PB ratio of Nectar Lifesciences Ltd (NECLIFE) stock?
The P/E (price-to-earnings) ratio of Nectar Lifesciences Ltd (NECLIFE) is -3.25. The P/B (price-to-book) ratio is 0.35.Which sector does Nectar Lifesciences Ltd (NECLIFE) belong to?
Nectar Lifesciences Ltd (NECLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nectar Lifesciences Ltd (NECLIFE) shares?
You can directly buy Nectar Lifesciences Ltd (NECLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nectar Lifesciences Ltd
NECLIFE Share Price
NECLIFE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
NECLIFE Performance & Key Metrics
NECLIFE Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-3.25 | 0.35 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
36.77 | 6.43 | 0.79% |
NECLIFE Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
NECLIFE Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
NECLIFE Forecast
NECLIFE Forecasts
NECLIFE
NECLIFE
Income
Balance Sheet
Cash Flow
NECLIFE Income Statement
NECLIFE Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,666.37 | 1,882.29 | 2,788.91 | 2,370.70 | 1,547.08 | 1,680.15 | 1,566.85 | 1,698.66 | 1,674.97 | 1,674.97 | ||||||||||
Raw Materials | 1,145.85 | 1,417.32 | 2,268.13 | 1,862.83 | 1,052.82 | 1,207.32 | 1,200.84 | 1,242.45 | 1,699.53 | 1,699.53 | ||||||||||
Power & Fuel Cost | 75.44 | 91.85 | 103.47 | 92.72 | 84.63 | 101.41 | 127.39 | 129.52 | ||||||||||||
Employee Cost | 75.54 | 74.65 | 76.54 | 78.19 | 70.59 | 71.91 | 75.14 | 81.71 | ||||||||||||
Selling & Administrative Expenses | 59.98 | 52.23 | 67.99 | 67.01 | 72.04 | 66.86 | 62.64 | 61.39 | ||||||||||||
Operating & Other expenses | 62.48 | 4.06 | 2.56 | 45.89 | 179.49 | 62.79 | 4.66 | 17.46 | ||||||||||||
EBITDA | 247.08 | 242.18 | 270.22 | 224.06 | 87.51 | 169.86 | 96.18 | 166.13 | -24.56 | -24.56 | ||||||||||
Depreciation/Amortization | 62.25 | 64.31 | 63.26 | 60.77 | 60.25 | 56.97 | 59.12 | 60.72 | 62.39 | 62.39 | ||||||||||
PBIT | 184.83 | 177.87 | 206.96 | 163.29 | 27.26 | 112.89 | 37.06 | 105.41 | -86.95 | -86.95 | ||||||||||
Interest & Other Items | 117.41 | 115.20 | 148.14 | 125.83 | 112.04 | 78.81 | 79.49 | 87.14 | 74.58 | 74.58 | ||||||||||
PBT | 67.42 | 62.67 | 58.82 | 37.46 | -84.78 | 34.08 | -42.43 | 18.27 | -161.53 | -161.53 | ||||||||||
Taxes & Other Items | 12.08 | 10.41 | 11.22 | 5.68 | -11.50 | 9.03 | -18.24 | 13.28 | -47.85 | -47.85 | ||||||||||
Net Income | 55.34 | 52.26 | 47.60 | 31.78 | -73.28 | 25.05 | -24.19 | 4.99 | -113.68 | -113.68 | ||||||||||
EPS | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -5.07 | ||||||||||
DPS | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.02 | 0.02 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NECLIFE Company Updates
NECLIFE Stock Peers
NECLIFE Past Performance & Peer Comparison
NECLIFE Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Nectar Lifesciences Ltd | -3.25 | 0.35 | — |
Sun Pharmaceutical Industries Ltd | 36.65 | 5.53 | 0.96% |
Cipla Ltd | 22.85 | 3.85 | 1.07% |
Torrent Pharmaceuticals Ltd | 59.39 | 14.95 | 0.18% |
NECLIFE Stock Price Comparison
Compare NECLIFE with any stock or ETFNECLIFE Holdings
NECLIFE Shareholdings
NECLIFE Promoter Holdings Trend
NECLIFE Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
A significant proportion of promoter holdings is pledged
NECLIFE Institutional Holdings Trend
NECLIFE Institutional Holdings Trend
In last 3 months, retail holding in the company has increased by 1.31%
In last 3 months, foreign institutional holding of the company has almost stayed constant
NECLIFE Shareholding Pattern
NECLIFE Shareholding Pattern
NECLIFE Shareholding History
NECLIFE Shareholding History
smallcases containing NECLIFE stock
smallcases containing NECLIFE stock
Looks like this stock is not in any smallcase yet.
NECLIFE Events
NECLIFE Events
NECLIFE Dividend Trend
NECLIFE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
NECLIFE Dividend Trend
NECLIFE has not given any dividends in last 5 years
NECLIFE Upcoming Dividends
NECLIFE Upcoming Dividends
No upcoming dividends are available
NECLIFE Past Dividends
NECLIFE Past Dividends
Cash Dividend
Ex DateEx DateSep 11, 2020
Dividend/Share
₹0.05
Ex DateEx Date
Sep 11, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 19, 2018
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2018
Cash Dividend
Ex DateEx DateSep 20, 2017
Dividend/Share
₹0.05
Ex DateEx Date
Sep 20, 2017
Cash Dividend
Ex DateEx DateSep 22, 2016
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2016
NECLIFE Stock News & Opinions
NECLIFE Stock News & Opinions
Lokesh Machines Ltd, Rhetan TMT Ltd, Vibhor Steel Tubes Ltd and Dreamfolks Services Ltd are among the other losers in the BSE's 'B' group today, 09 July 2025.Nectar Lifescience Ltd tumbled 9.93% to Rs 16.69 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 28.52 lakh shares were traded on the counter so far as against the average daily volumes of 2.2 lakh shares in the past one month.Lokesh Machines Ltd crashed 7.85% to Rs 218.85. The stock was the second biggest loser in 'B' group.On the BSE, 42757 shares were traded on the counter so far as against the average daily volumes of 12459 shares in the past one month.Rhetan TMT Ltd lost 7.75% to Rs 17.49. The stock was the third biggest loser in 'B' group.On the BSE, 21.83 lakh shares were traded on the counter so far as against the average daily volumes of 6.83 lakh shares in the past one month.Vibhor Steel Tubes Ltd slipped 5.35% to Rs 182.3. The stock was the fourth biggest loser in 'B' group.On the BSE, 6454 shares were traded on the counter so far as against the average daily volumes of 9926 shares in the past one month.Dreamfolks Services Ltd dropped 5.29% to Rs 167.55. The stock was the fifth biggest loser in 'B' group.On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 1.15 lakh shares in the past one month.Powered by Capital Market - Live
Nectar Lifescience announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 August 2025.Powered by Capital Market - Live
Rajdarshan Industries Ltd, Sharda Motor Industries Ltd, PC Jeweller Ltd and PVP Ventures Ltd are among the other losers in the BSE's 'B' group today, 08 July 2025.Nectar Lifescience Ltd tumbled 19.99% to Rs 18.53 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 22 lakh shares were traded on the counter so far as against the average daily volumes of 1.27 lakh shares in the past one month.Rajdarshan Industries Ltd crashed 8.51% to Rs 52.6. The stock was the second biggest loser in 'B' group.On the BSE, 2204 shares were traded on the counter so far as against the average daily volumes of 1544 shares in the past one month.Sharda Motor Industries Ltd lost 7.27% to Rs 1132.25. The stock was the third biggest loser in 'B' group.On the BSE, 25991 shares were traded on the counter so far as against the average daily volumes of 8659 shares in the past one month.PC Jeweller Ltd plummeted 6.78% to Rs 17.45. The stock was the fourth biggest loser in 'B' group.On the BSE, 356.88 lakh shares were traded on the counter so far as against the average daily volumes of 91.41 lakh shares in the past one month.PVP Ventures Ltd fell 6.06% to Rs 20.91. The stock was the fifth biggest loser in 'B' group.On the BSE, 1.21 lakh shares were traded on the counter so far as against the average daily volumes of 26062 shares in the past one month.Powered by Capital Market - Live
The deal, executed on a slump sale basis, includes the manufacture, distribution, and marketing of APIs (active pharmaceutical ingredients) and formulations. As part of the broader restructuring, Nectar has also signed an asset purchase agreement to divest its menthol business assets to Ceph Lifesciences for an additional Rs 20 crore. The transaction, expected to be completed by 20 September 2025, is subject to shareholder approval at an extraordinary general meeting scheduled for August 4. According to the company, this sale marks a significant pivot toward becoming a more focused and innovation-driven enterprise. Proceeds from the deal will be used to repay existing debt, invest in emerging opportunities, potentially reward shareholders and fund future growth initiatives. The buyer, Ceph Lifesciences, is a non-promoter entity with no impact on Nectar's existing shareholding pattern post-transaction. Sanjiv Goyal, promoter and chairman of Nectar Lifesciences, commented: This transaction marks a significant milestone in Nectar Lifesciences' evolution. By divesting mature segments of our business, we are laying the foundation for a focused and agile organization geared towards innovation and long-term value creation. We thank our stakeholders for their continued trust and support as we embark on this next chapter. Nectar Lifesciences is a pharmaceutical company focused on research-driven innovation, manufacturing, and global distribution. The company will announce Q4 results on 7 July 2025. On a consolidated basis, net profit of Nectar Lifescience soared 399.36% to Rs 7.84 crore while net sales rose 0.48% to Rs 454.33 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 7 July 2025.Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards. Following the inspection, seven observations including four critical, were noted. Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards. The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval. Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab. The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales454.33452.16 0 OPM %9.849.33 - PBDT28.1617.83 58 PBT12.552.46 410 NP7.841.57 399 Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales427.88397.96 8 OPM %10.136.75 - PBDT24.2116.95 43 PBT8.671.64 429 NP5.601.02 449 Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -6.71%, vs industry avg of 10.1%
Over the last 5 years, market share decreased from 0.94% to 0.4%